Transgene — developer of TG4050 (myvac), a viral-vector personalized neoantigen vaccine built on the myvac/NEC AI platform.
January 09, 2026 02:00 ET | Source: Transgene S.A. Transgene S.A. TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 potential as an individualized cancer immunotherapy Strasbourg, Franc…
Transgene SA is expanding its pipeline of individualized neoantigen therapeutic vaccines into early-stage non-small cell lung cancer (NSCLC). The company’s recent updates highlight progress in developing personalized immunotherapies beyond their current indications, signaling an effort to diversify the application of their neoantigen platform across major oncology markets.
Transgene is expanding its myvac platform into non-small cell lung cancer (NSCLC) with TG4070, an individualized neoantigen therapeutic vaccine. This move marks a commercial progression for the company’s personalized vaccine approach beyond previous indications.
Transgene has announced the expansion of its myvac® platform into NSCLC via TG4070, an individualized neoantigen therapeutic vaccine. The company is leveraging its proprietary technology to target personalized antigens in this major solid tumor indication, marking a strategic broadening of its commercial pipeline beyond previous indications.
Reports confirm Transgene's entry of TG4070 into the NSCLC market as part of its myvac® portfolio. By targeting individualized neoantigens, Transgene aims to capitalize on the growing commercial interest in personalized cancer vaccines, positioning TG4070 as a key asset in its expanding therapeutic lineup.
Transgene is advancing TG4070, an individualized neoantigen vaccine under its myvac® platform, into non-small cell lung cancer. This development highlights the company's strategy to apply its personalized vaccine technology across multiple solid tumor types, though no specific trial phases or efficacy outcomes were disclosed in the current reports.
Transgene reported positive randomized Phase I data for its individualized neoantigen therapeutic cancer vaccine, TG4050. The company plans to complete randomization for the Phase II part of the trial in Q4 2025, marking a key milestone in the program's clinical progression.